search
Back to results

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Primary Purpose

Advanced Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
RP-3500 (camonsertib)
Talazoparib
Gemcitabine Injection
Sponsored by
Repare Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor focused on measuring Adult

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent, according to local guidelines, signed and dated by the patient or legal guardian prior to the performance of any study-specific procedures, sampling, or analyses.
  • Male or female and ≥ 18 years-of-age at the time of signature of the consent.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
  • Histologically confirmed solid tumors resistant or refractory to standard treatment and/or patients who are intolerant to standard therapy.
  • Measurable disease as per RECIST v1.1
  • Existing biomarker profile (tumor tissue or plasma) reported from a local test obtained in a certified lab per institutional guidelines:
  • Available tumor tissue
  • Ability to comply with the protocol and study procedures detailed in the Schedule of Assessments.
  • Ability to swallow and retain oral medications.
  • Acceptable organ function at screening
  • Acceptable blood counts at screening
  • Negative pregnancy test (serum or urine) for females of childbearing potential at Screening and prior to first study drug.
  • Resolution of all toxicities of prior treatment or surgery.
  • Male patients with female partners of childbearing potential and females of childbearing potential must follow a contraception method (oral contraceptives allowed) during their participation in the study and for at least 6 months following last dose of study drug. Male patients must also refrain from donating sperm during their participation in the study and for 6 months following last dose of study drug.

Exclusion Criteria:

  • Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 14 days prior to first dose of study drug.
  • History or current condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
  • Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor.
  • Known hypersensitivity to any of the ingredients of RP-3500.
  • Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the patient's safety.
  • Uncontrolled, symptomatic brain metastases.
  • Uncontrolled high blood pressure
  • Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
  • Moderate or severe hepatic impairment (ie, Child-Pugh class B or C).
  • History or presence of an abnormal ECG that is clinically significant in the investigator's opinion.
  • History of ventricular dysrhythmias or risk factors such as structural heart disease, coronary heart disease (clinically significant electrolyte abnormalities or family history of sudden unexplained death or long QT syndrome
  • Current treatment with medications that are well-known to prolong the QT interval
  • History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis

Sites / Locations

  • Participating Site 1014Recruiting
  • Participating Site 1006Recruiting
  • Participating Site 1002Recruiting
  • Participating Site 1004Recruiting
  • Participating Site 1005Recruiting
  • Participating Site 1007Recruiting
  • Participating Site 1003
  • Participating Site 1001Recruiting
  • Participating Site 2001Recruiting
  • Participating Site 4001Recruiting
  • Participating Site 3003Recruiting
  • Participating Site 3001Recruiting
  • Participating Site 3002Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

RP-3500 (camonsertib) alone

Expansion cohorts with RP-3500 (camonsertib)

RP-3500 (camonsertib) with Talazoparib or Gemcitabine

Arm Description

Phase 1: Multiple doses of RP-3500 (camonsertib) for oral administration alone

Phase 2: Expansion cohorts with RP-3500 (camonsertib)

Phase 1: Multiple doses of RP-3500 (camonsertib) for oral administration in combination with talazoparib or gemcitabine

Outcomes

Primary Outcome Measures

To define the Maximum Tolerated Dose (MTD) which will then be used to inform and determine the Recommended Phase 2 Dose (RP2D) and schedule alone or in combination with talazoparib or gemcitabine
Frequency of Dose limiting Toxicities (DLTs)
Safety and tolerability
Grade and frequency of adverse events and serious adverse events

Secondary Outcome Measures

Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1) or confirmed response in CA-125 or PSA per GCIG or PSWG criteria.
Overall response rate
Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1)
Objective response rate (ORR)
Assess CR+PR+SD (≥ 4 months) based on RECIST v1.1, confirmed CA-125 response by GCIG criteria, or PSA response based on PCWG3
Clinical Benefit Rate
Assess preliminary anti-tumor activity with Duration of Response (DOR) in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1).
Duration of response (DOR)
Characterize the pharmacokinetic profile of RP-3500 (camonsertib)
Area-under-the-curve (AUC 0-inf)
Peak plasma concentration
Cmax
To assess PK parameters of RP-3500 (camonsertib) monotherapy in fasted and fed states
Comparison of geometric mean ratios (GMR)
Pharmacodynamic biomarkers of DNA damage (e.g. gH2AX) will be measured by immunohistochemistry and the percentage of positive cells will be compared between the pre and post treatment biopsies to evaluate target engagement
Tumor tissue samples will be collected pre and post dosing

Full Information

First Posted
July 21, 2020
Last Updated
August 1, 2023
Sponsor
Repare Therapeutics
Collaborators
Roche Pharma AG
search

1. Study Identification

Unique Protocol Identification Number
NCT04497116
Brief Title
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
Official Title
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 22, 2020 (Actual)
Primary Completion Date
January 30, 2024 (Anticipated)
Study Completion Date
March 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Repare Therapeutics
Collaborators
Roche Pharma AG

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a PARP inhibitor, or Gemcitabine in patients with advanced solid tumors with ATR inhibitor-sensitizing mutations. This study will also evaluate the safety and tolerability of RP-3500 (camonsertib) alone or in combination with talazoparib or gemcitabine, examine both the pharmacokinetics (PK)and pharmacodynamics (PD)and investigate its anti-tumor activity in solid tumors.
Detailed Description
This is a first-in-human, Phase 1/2a, multi-center, open-label, dose-escalation and expansion study to: Evaluate the safety profile and MTD of RP-3500 (camonsertib) when administered orally, alone and in combination with talazoparib or gemcitabine, to establish the dose and schedule recommended for the Phase 2 Characterize the PK profile of RP-3500 (camonsertib) alone or in combination with talazoparib or gemcitabine Identify anti-tumor activity associated with RP-3500 (camonsertib) given alone or in combination with talazoparib or gemcitabine Examine biomarker responses and establish a correlation with RP-3500 (camonsertib) exposure and clinical outcomes. The initial cohorts will test RP-3500 (camonsertib) as monotherapy. Additional cohorts will enroll with RP-3500 (camonsertib) in combination with talazoparib or gemcitabine. After the RP2D and schedule is determined, expansion cohort(s) for RP-3500 (camonsertib) will be enrolled to study the anti-tumor effect, and further examine the safety and PK of RP-3500 (camonsertib) at the RP2D

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor
Keywords
Adult

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
Dose Escalation, expansion and phase 2
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
451 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RP-3500 (camonsertib) alone
Arm Type
Experimental
Arm Description
Phase 1: Multiple doses of RP-3500 (camonsertib) for oral administration alone
Arm Title
Expansion cohorts with RP-3500 (camonsertib)
Arm Type
Experimental
Arm Description
Phase 2: Expansion cohorts with RP-3500 (camonsertib)
Arm Title
RP-3500 (camonsertib) with Talazoparib or Gemcitabine
Arm Type
Experimental
Arm Description
Phase 1: Multiple doses of RP-3500 (camonsertib) for oral administration in combination with talazoparib or gemcitabine
Intervention Type
Drug
Intervention Name(s)
RP-3500 (camonsertib)
Intervention Description
Oral ATR inhibitor
Intervention Type
Drug
Intervention Name(s)
Talazoparib
Intervention Description
Oral PARP inhibitor
Intervention Type
Drug
Intervention Name(s)
Gemcitabine Injection
Intervention Description
Gemcitabine
Primary Outcome Measure Information:
Title
To define the Maximum Tolerated Dose (MTD) which will then be used to inform and determine the Recommended Phase 2 Dose (RP2D) and schedule alone or in combination with talazoparib or gemcitabine
Time Frame
Up to 90 days after last administration of study intervention
Title
Frequency of Dose limiting Toxicities (DLTs)
Time Frame
At the end of cycle 1 (each cycle is 21 days or 28 days)
Title
Safety and tolerability
Description
Grade and frequency of adverse events and serious adverse events
Time Frame
Up to 90 days after last administration of study intervention
Secondary Outcome Measure Information:
Title
Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1) or confirmed response in CA-125 or PSA per GCIG or PSWG criteria.
Description
Overall response rate
Time Frame
About 1 year
Title
Assess preliminary anti-tumor activity with Overall Response Rate in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1)
Description
Objective response rate (ORR)
Time Frame
About 1 year
Title
Assess CR+PR+SD (≥ 4 months) based on RECIST v1.1, confirmed CA-125 response by GCIG criteria, or PSA response based on PCWG3
Description
Clinical Benefit Rate
Time Frame
About 1 year
Title
Assess preliminary anti-tumor activity with Duration of Response (DOR) in patients with eligible advanced solid tumors by CT/MRI Response evaluation criteria in solid tumors (RECIST 1.1).
Description
Duration of response (DOR)
Time Frame
About 1 year
Title
Characterize the pharmacokinetic profile of RP-3500 (camonsertib)
Description
Area-under-the-curve (AUC 0-inf)
Time Frame
Through Study Day 152
Title
Peak plasma concentration
Description
Cmax
Time Frame
Through Study Day 152
Title
To assess PK parameters of RP-3500 (camonsertib) monotherapy in fasted and fed states
Description
Comparison of geometric mean ratios (GMR)
Time Frame
Through Study Day 152
Title
Pharmacodynamic biomarkers of DNA damage (e.g. gH2AX) will be measured by immunohistochemistry and the percentage of positive cells will be compared between the pre and post treatment biopsies to evaluate target engagement
Description
Tumor tissue samples will be collected pre and post dosing
Time Frame
Through Study Day -28 to Day 66 (each cycle is 21 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent, according to local guidelines, signed and dated by the patient or legal guardian prior to the performance of any study-specific procedures, sampling, or analyses. Male or female and ≥ 18 years-of-age at the time of signature of the consent. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. Histologically confirmed solid tumors resistant or refractory to standard treatment and/or patients who are intolerant to standard therapy. Measurable disease as per RECIST v1.1 Existing biomarker profile (tumor tissue or plasma) reported from a local test obtained in a certified lab per institutional guidelines: Available tumor tissue Ability to comply with the protocol and study procedures detailed in the Schedule of Assessments. Ability to swallow and retain oral medications. Acceptable organ function at screening Acceptable blood counts at screening Negative pregnancy test (serum or urine) for females of childbearing potential at Screening and prior to first study drug. Resolution of all toxicities of prior treatment or surgery. Male patients with female partners of childbearing potential and females of childbearing potential must follow a contraception method (oral contraceptives allowed) during their participation in the study and for at least 6 months following last dose of study drug. Male patients must also refrain from donating sperm during their participation in the study and for 6 months following last dose of study drug. Exclusion Criteria: Chemotherapy, small molecule anticancer or biologic anticancer therapy given within 14 days prior to first dose of study drug. History or current condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment. Prior therapy with an ATR or DNA-dependent protein kinase (DNA-PK) inhibitor. Known hypersensitivity to any of the ingredients of RP-3500 (camonsertib). Life-threatening illness, medical condition, active uncontrolled infection, or organ system dysfunction or other reasons which, in the investigator's opinion, could compromise the patient's safety. Uncontrolled, symptomatic brain metastases. Uncontrolled high blood pressure Patients with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness. Moderate or severe hepatic impairment (ie, Child-Pugh class B or C). History or presence of an abnormal ECG that is clinically significant in the investigator's opinion. History of ventricular dysrhythmias or risk factors such as structural heart disease, coronary heart disease (clinically significant electrolyte abnormalities or family history of sudden unexplained death or long QT syndrome Current treatment with medications that are well-known to prolong the QT interval History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gabriela Gomez, MD, MBA
Phone
857-340-5415
Email
clininfo@reparerx.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy A Yap, MBBS PhD FRCP
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Participating Site 1014
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Name
Participating Site 1006
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Name
Participating Site 1002
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Name
Participating Site 1004
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Name
Participating Site 1005
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Name
Participating Site 1007
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Individual Site Status
Recruiting
Facility Name
Participating Site 1003
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Participating Site 1001
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Participating Site 2001
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Name
Participating Site 4001
City
Copenhagen
State/Province
DK
ZIP/Postal Code
2100 Ø
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Participating Site 3003
City
London
ZIP/Postal Code
W1G 6AD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Participating Site 3001
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Participating Site 3002
City
Newcastle Upon Tyne
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

We'll reach out to this number within 24 hrs